Compounds > mozavaptan
Page last updated: 2024-09-03

mozavaptan and 1-(beta-mercapto-beta,beta-cyclopentamethylenepropionic acid)-2-(o-ethyl-tyr)-4-val-arginine vasopressin

mozavaptan has been researched along with 1-(beta-mercapto-beta,beta-cyclopentamethylenepropionic acid)-2-(o-ethyl-tyr)-4-val-arginine vasopressin in 1 studies

Compound Research Comparison

Studies
(mozavaptan)		Trials
(mozavaptan)		Recent Studies (post-2010)
(mozavaptan)		Studies
(1-(beta-mercapto-beta,beta-cyclopentamethylenepropionic acid)-2-(o-ethyl-tyr)-4-val-arginine vasopressin)		Trials
(1-(beta-mercapto-beta,beta-cyclopentamethylenepropionic acid)-2-(o-ethyl-tyr)-4-val-arginine vasopressin)		Recent Studies (post-2010) (1-(beta-mercapto-beta,beta-cyclopentamethylenepropionic acid)-2-(o-ethyl-tyr)-4-val-arginine vasopressin)
1658243500

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Fujisawa, G; Ishikawa, S; Okada, K; Saito, T; Tsuboi, Y1

Other Studies

1 other study(ies) available for mozavaptan and 1-(beta-mercapto-beta,beta-cyclopentamethylenepropionic acid)-2-(o-ethyl-tyr)-4-val-arginine vasopressin

ArticleYear
Therapeutic efficacy of the non-peptide AVP antagonist OPC-31260 in cirrhotic rats.
    Kidney international, 1994, Volume: 46, Issue:1

    Topics: Animals; Arginine Vasopressin; Benzazepines; Blood Pressure; Body Weight; Diuresis; Glomerular Filtration Rate; Liver Cirrhosis, Experimental; Male; Osmolar Concentration; Rats; Rats, Wistar; Vasopressins; Water-Electrolyte Balance

1994